Preparation and Cytotoxic Evaluation of PGV-1 Derivative, CCA-1.1, as a New Curcumin Analog with Improved-Physicochemical and Pharmacological Properties

Rohmad Yudi Utomo ^1,2 , Febri Wulandari ¹ , Dhania Novitasari ¹ , Beni Lestari ¹ , Ratna Asmah Susidarti ^1,2 , Riris Istighfari Jenie ^1,3 , Jun-ya Kato ⁴, Sardjiman Sardjiman ² , Edy Meiyanto ^1,3 *

Cited by CrossRef: 3

1- Ardiansah B, Hardhani M, Putera D, Wukirsari T, Cahyana A, Jia J, Khan M. Design, synthesis, and antioxidant evaluation of monocarbonyl curcumin analogues tethered 1,2,3-triazole scaffold. Case Studies in Chemical and Environmental Engineering. 2023;8:100425 [Crossref]

2- Hermawan A, Wulandari F, Hanif N, Utomo R, Jenie R, Ikawati M, Tafrihani A. Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment : integrated computational analysis and in vitro study. Sci Rep. 2022;12(1) [Crossref]

3- Wulandari F, Ikawati M, Widyarini S, Kirihata M, Novitasari D, Kato J, Meiyanto E. Tumour-suppressive effects of curcumin analogs CCA-1.1 and Pentagamavunone-1 in colon cancer: In vivo and in vitro studies. J Adv Pharm Technol Res. 2023;14(4):317 [Crossref]

4- Novitasari D, Jenie R, Kato J, Meiyanto E. Chemoprevention curcumin analog 1.1 promotes metaphase arrest and enhances intracellular reactive oxygen species levels on TNBC MDA-MB-231 and HER2-positive HCC1954 cells. 2023;18(4):358 [Crossref]